Founded in 2011 in Amsterdam, Optics11 Life builds a portfolio of mechanobiology tools—Pavone, Piuma, Chiaro, and Cuore—that perform high-throughput nano-indentation and 3D contractility measurements on cells, tissues, and biomaterials. The company combines fibre-optic sensing with automation and imaging to generate data that improve drug development workflows, enable disease modelling, and support quality control in regenerative medicine. Its technology also underpins New Approach Methodologies (NAMs) aimed at reducing or eliminating animal testing. With a team of more than 60 employees, Optics11 Life serves academic and commercial laboratories in the US, Europe, and Asia. The newly secured capital will be channelled into further instrument development, an expanded global sales footprint, and a broader product roadmap. Management positions the company to help customers create accessible, affordable, and effective therapies while decreasing reliance on animal models. No revenue or user figures were disclosed in the article.

Total raised

$5M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2022